Sanara Medtech Inc Cash Flow Conversion Efficiency
Sanara Medtech Inc cash flow conversion efficiency. Based on the latest financial reports, Sanara Medtech Inc (SMTI) has a cash flow conversion efficiency ratio of 0.257x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.04 Million) by net assets ($7.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sanara Medtech Inc (1999–2025)
Cash flow conversion efficiency of Sanara Medtech Inc from 1999 to 2025. This chart illustrates how Sanara Medtech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sanara Medtech Inc (SMTI) share price today for real-time trading data and today's change.
Sanara Medtech Inc Cash Flow Conversion Ratio Explained
Sanara Medtech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sanara Medtech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanara Medtech Inc ranked by their cash flow conversion efficiency. Also see SMTI market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sangsangin Investment & Securities Co Ltd
KO:001290
|
-0.443x |
|
RPSG VENTURES LIMITED
NSE:RPSGVENT
|
0.209x |
|
Good Will Instrument Co Ltd
TW:2423
|
-0.008x |
|
Idun Industrier AB Series B
ST:IDUN-B
|
0.091x |
|
KGI Securities (Thailand) Public Company Limited
BK:KGI
|
0.180x |
|
Zhengzhou Tiamaes Technology Co Ltd
SHE:300807
|
0.023x |
|
Sprott Focus Trust
NASDAQ:FUND
|
N/A |
|
Advancetek Enterprise Co Ltd
TW:1442
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Sanara Medtech Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Sanara Medtech Inc from 1999 to 2025. Review Sanara Medtech Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.93 Million | $6.79 Million | 1.145x | +187346.65% |
| 2024-12-31 | $38.91 Million | $-23.78K | -0.001x | +99.16% |
| 2023-12-31 | $44.59 Million | $-3.25 Million | -0.073x | +45.33% |
| 2022-12-31 | $41.72 Million | $-5.55 Million | -0.133x | +16.61% |
| 2021-12-31 | $30.15 Million | $-4.81 Million | -0.160x | +76.89% |
| 2020-12-31 | $5.84 Million | $-4.03 Million | -0.691x | -103.74% |
| 2019-12-31 | $6.39 Million | $-2.17 Million | -0.339x | -236.05% |
| 2018-12-31 | $1.11 Million | $277.14K | 0.249x | +118.27% |
| 2017-12-31 | $102.54K | $-139.86K | -1.364x | -41.01% |
| 2016-12-31 | $-423.07K | $409.25K | -0.967x | -202.23% |
| 2015-12-31 | $-1.27 Million | $-1.20 Million | 0.946x | -53.70% |
| 2014-12-31 | $-825.40K | $-1.69 Million | 2.043x | +176.87% |
| 2013-12-31 | $-2.47 Million | $-1.82 Million | 0.738x | +129.08% |
| 2012-12-31 | $-3.81 Million | $-1.23 Million | 0.322x | +261.94% |
| 2011-12-31 | $-3.86 Million | $-343.60K | 0.089x | +117.11% |
| 2010-12-31 | $2.87 Million | $-1.49 Million | -0.520x | +7.01% |
| 2009-12-31 | $2.31 Million | $-1.30 Million | -0.560x | -116.99% |
| 2008-12-31 | $-321.26K | $-1.06 Million | 3.295x | +1468.87% |
| 2007-12-31 | $-1.81 Million | $-380.90K | 0.210x | -33.10% |
| 2006-12-31 | $-1.27 Million | $-398.97K | 0.314x | -67.45% |
| 2005-12-31 | $-647.47K | $-624.45K | 0.964x | +107.24% |
| 2004-12-31 | $41.20K | $-548.46K | -13.313x | -3955.33% |
| 2001-12-31 | $-2.10 Million | $-723.86K | 0.345x | -16.37% |
| 2000-12-31 | $-1.38 Million | $-569.36K | 0.413x | -75.18% |
| 1999-12-31 | $-377.38K | $-627.86K | 1.664x | -- |
About Sanara Medtech Inc
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and seco… Read more